Abstract 1503P
Background
Spirituality is important in cancer care. Few studies have assessed the spiritual needs (SN) of cancer patients. The purpose of this study was to assess the SN of patients undergoing curative or palliative cancer treatments, and to evaluate the relationship between SN and their health-related quality of life (QOL).
Methods
We conducted a cross-sectional study using a brief questionnaire on the healthcare team's approach to spirituality, the Duke University Religion Index (DUREL), the Functional Assessment of Chronic Illness Therapy Spiritual Well Being Version 4 (FACIT-SP), and the Spiritual Needs Assessment for Patients (SNAP) in outpatient adults with solid tumors undergoing curative-intent or palliative cancer treatments. Informed consent was obtained from all patients.
Results
From March to October/2022, 150 patients were included: 75 receiving curative-intent treatment and 75, palliative. Patients who wanted a spirituality approach by the healthcare team had higher total SN and psychosocial, spiritual, and religious scores than patients who did not want it (p < 0.0001), but lower QOL scores (FACIT-G p = 0.001 and FACIT-SP p = 0.004). SN or QOL did not differ according to treatment intention (p = 0,444 and p = 0,159 respectively), age (r = 0,059), education level (p = 0,999), sex (p = 0,186), or marital status (p = 0,528). There was a predominant weak correlation between SN and QOL (r < 0,4); a moderate negative relationship between emotional well-being and spiritual domain needs (r = -0,416); a weak correlation between SN and the three dimensions of DUREL (r < 0,4); a moderate positive relationship (0,461 < r < 0,616) between faith subscale of spiritual well-being and the three dimensions of DUREL; and also, a moderate positive relationship (r = 0,410) between spiritual well-being and intrinsic religiosity.
Conclusions
In our study, patients who wanted a spiritual approach from the healthcare team had higher SN and lower QOL. SN were not related to cancer treatment intentions or the patient religiosity. Assessment of spirituality may improve cancer care, and further studies could evaluate screening and interventions in this area.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10